Безопасность лекарственных растительных препаратов: клинико-фармакологические аспекты

Лекарственные растительные препараты широко представлены в общем ассортименте российского рынка лекарственных средств. Сложный комплекс биологически активных веществ, содержащихся в таких препаратах, определяет не только их терапевтическую эффективность, но и может стать причиной возникновения нежелательных реакций. Цель работы: анализ информации о нежелательных реакциях, причинах и особенностях их возникновения при применении лекарственных растительных препаратов. Показано, что гепатотоксическое и нефротоксическое действие биологически активных веществ таких препаратов требуют особого внимания, поскольку нарушения со стороны печени и почек могут сопровождаться развитием состояний, угрожающих жизни. Подробно рассмотрены нежелательные реакции со стороны печени, в том числе синдром синусоидальной обструкции, вызываемые токсичными биологически активными веществами из группы пирролизидиновых алкалоидов. Систематизированы данные о лекарственных препаратах растительного происхождения и токсичных биологически активных веществах, вызывающих острые и хронические формы повреждения почек. Проанализированы возможные клинически значимые взаимодействия, возникающие при совместном применении лекарственных растительных препаратов с другими лекарственными средствами вследствие фармакокинетических и фармакодинамических взаи­модействий. Для повышения безопасности фармакотерапии необходимо продолжение исследований по сбору, систематизации и анализу информации о нежелательных реакциях, возникающих при применении лекарственных растительных препаратов в виде монотерапии и в сочетании с другими лекарственными препаратами.

1. Самбукова ТВ, Овчинников БВ, Ганапольский ВП, Ятманов АН, Шабанов ПД. Перспективы использования фитопрепаратов в современной фармакологии. Обзоры по клинической фармакологии и лекарственной терапии. 2017;15(2):56–63. https://doi.org/10.17816/RCF15256-63

2. Бойко НН, Бондарев АВ, Жилякова ЕТ, Писарев ДИ, Новиков ОО. Фитопрепараты, анализ фармацевтического рынка Российской Федерации. Научный результат. Медицина и фармация. 2017;3(4):30–8. https://doi.org/10.18413/2313-8955-2017-3-4-30-38

3. Миронов АН, Сакаева ИВ, Саканян ЕИ, Корсун ЛВ, Мочикина ОА. Современные подходы к вопросу стандартизации лекарственного растительного сырья. Ведомости Научного центра экспертизы средств медицинского применения. 2013;(2):52–6.

4. Акамова АВ, Немятых ОД, Наркевич ИА. Многовекторный маркетинговый анализ российского рынка фитопрепаратов. Разработка и регистрация лекарственных средств. Разработка и регистрация лекарственных средств. 2017;4(21):276–80.

5. Izzo AA, Hoon‐Kim S, Radhakrishnan R, Williamson EM. A critical approach to evaluating clinical efficacy, adverse evants and drug intervactions of herbal remedies. Phytother Res. 2016;30(5):691–700. https://doi.org/10.1002/ptr.5591

6. Ших ЕВ, Булаев ВМ, Демидова ОА, Сокова ЕА. Взаимодействие биологически активных веществ лекарственных растительных препаратов с другими фармакотерапевтическими средствами. Ведомости Научного центра экспертизы средств медицинского применения. 2016;(4):48–52.

7. Саканян ЕИ, Шемерянкина ТБ, Малкина ЮК, Лякина МН, Постоюк НА. Современные подходы к оценке эффективности и безопасности лекарственных средств растительного происхождения в России и за рубежом. Ведомости Научного центра экспертизы средств медицинского применения. 2015;(1):35–9.

8. De Smet PAGM. Health risks of herbal remedies: an update. Clin Pharmacol Ther. 2004;76(1):1–17. https://doi.org/10.1016/j.clpt.2004.03.005

9. Posadzki P, Watson LK, Ernst E. Adverse effects of her­bal medicines: an overview of systematic reviews. Clin Med. 2013;13(1):7–12. https://doi.org/10.7861/clinmedicine.13-1-7

10. Di Lorenzo C, Ceschi A, Kupferschmidt H, Lüde S, De Souza Nascimento E, Dos Santos A, et al. Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evalution of causality. Br J Clin Pharmacol. 2015;79(4):578–92. https://doi.org/10.1111/bcp.1251

11. Самылина ИА, Булаев ВМ. Проблемы безопасности лекарственных растений, содержащих эндогенные токсичные вещества. Фармация. 2009;(3):6–8.

12. Крепкова ЛВ, Бортникова ВВ, Сокольская ТА. Некоторые аспекты токсикологического изучения лекарственных препаратов на основе лекарственного растительного сырья. Фундаментальные исследования. 2013;(9):256–8.

13. Nedelcheva A, Kostova N, Sidjimov A. Pyrrolizide alkaloids in Tussilago farfara from Bulgaria. Biotechnology & Biotechnologocal Equipment. 2015;29(S1):S1–S7. https://doi.org/10.1080/13102818.2015.1047149

14. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;(4):177. https://doi.org/10.3389/fphar.2013.00177

15. Calitz C, du Plessis L, Gouws C, Steyn D, Steenekamp J, Muller C, Hamman S. Herbal hepatotoxicity: current status, examples, and challenges. Expert Opin Drug Metab Toxicol. 2015;11(10):1551–65. https://doi.org/10.1517/17425255.2015.1064110

16. Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363–73. https://doi.org/10.1002/hep.28813

17. Byeon JH, Kil JH, Ahn YC, Son CG. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019;233:190–6. https://doi.org/10.1016/j.jep.2019.01.006

18. Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019;156(8):2230–41.e11. https://doi.org/10.1053/j.gastro.2019.02.002

19. Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis. 2014;34(2):172–93. https://doi.org/10.1055/s-0034-1375958

20. Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol. 2015;6:72. https://doi.org/10.3389/fphar.2015.00072

21. Larrey D. Complementary and alternative medicine hepatotoxi­city. In: Andrade RJ, ed. Hepatotoxicity. Permanyer publications; 2007. P. 125–135.

22. Larrey D, Faure S. Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J Hepatology. 2011;54(4):599–601. https://doi.org/10.1016/j.jhep.2010.12.003

23. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37(1):3–17. https://doi.org/10.1111/apt.12109

24. Булаев ВМ, Ших ЕВ, Сычев ДА. Безопасность и эффективность лекарственных растений. М.: Практическая медицина; 2013.

25. He S, Zhang C, Zhou P, Zhang X, Ye T, Wang R, et al. Herb induced liver injury: phylogenetic relationship, structure-toxicity relationship and herb-ingredient network analysis. Int J Mol Sci. 2019;20(15):3633. https://doi.org/10.3390/ijms20153633

26. Adamczak A, Opala B, Gryszczyńska A, Buchwald W. Content of pyrrolizide alkaloids in the leaves of coltsfoot (Tussilago farfara L.) in Poland. Acta Societatis Botanicorum Poloniae. 2013;82(4):289–93. https://doi.org/10.5586/asbp.2013.028

27. Serment OC, Olaru OT, Gutu CM, Nitulescu GM, Ilie M, Negres S, et al. Toxicity of plant extracts containing pyrrolizide alkaloids using alternative invertebrate models. Mol Med Rep. 2018;17(6):7757–63. https://doi.org/10.3892/mmr.2018.8795

28. Fu PP, Xia Q, Lin G, Chou MW. Pyrrolizidine alkaloids — genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004;36(1):1–55. https://doi.org/10.1081/dmr-120028426

29. Dai N, Yu YC, Ren TH, Wu JG, Jiang Y, Shen LG, Zhang J. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol. 2007;13(10):1628–31. https://doi.org/10.3748/wjg.v13.i10.1628

30. Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther. 2006;23(1):11–25. https://doi.org/10.1111/j.1365-2036.2006.02742.x

31. Yang MB, Ruan JQ, Fu PP, Lin G. Cytotoxicity of pyrrolizidine alkaloids in human hepatic parenchymal and sinusoidal endothelial cells: firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chem Biol Interact. 2016;243:119–26. https://doi.org/10.1016/j.cbi.2015.09.011

32. Ruan J, Gao H, Li N, Xue J, Chen J, Ke C, et al. Blood pyrrole-protein adducts—a biomarker of pyrrolizidine alkaloid-induced liver injury in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33(4):404–21. https://doi.org/10.1080/10590501.2015.1096882

33. Gao H, Ruan J, Chen J, Li N, Ke CQ, Ye Y, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic indexin pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Devel Ther. 2015;9:4861–8. https://doi.org/10.2147/DDDT.S87858

34. Yang M, Ruan J, Gao H, Li N, Ma J, Xue J, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol. 2017;91(12):3913–25. https://doi.org/10.1007/s00204-017-2013-y

35. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222–61. https://doi.org/10.1016/j.jhep.2019.02.014

36. Gao L, Schmitz HJ, Merz KH, Schrenk D. Characterization of the cytotoxicity of selected Chelidonium alkaloids in rat hepatocytes. Toxicol Lett. 2019;311:91–7. https://doi.org/10.1016/j.toxlet.2019.04.031

37. Wu C, Wang Y, Xu M, Liu Y, Di X. Intracellular accumulation as an cytotoxicity to screen hepatotoxic components of Chelidonium majus L. by LC–MS/MS. Molecules. 2019;24(13):2410. https://doi.org/10.3390/molecules24132410

38. Zhou P, Gross S, Liu JH, Yu BY, Feng LL, Nolta J, et al. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. FASEB J. 2010;24(12):4722–32. https://doi.org/10.1096/fj.10.163311

39. Haouzi D, Lekéhal M, Moreau A, Moulis C, Feldmann G, Ro­bin MA, et al. Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology. 2000;32(2):303–11. https://doi.org/10.1053/jhep.2000.9034

40. Rader JI, Delmonte P, Trucksess MW. Recent studies on selected botanical dietary supplement ingredients. Anal Bioanal Chem. 2007;389(1):27–35. https://doi.org/10.1007/s00216-007-1254-7

41. Choen DL, Toro YD. A case of valerian-associated hepatotoxi­city. J Clin Gastroenterol. 2008;42(8):961–2. https://doi.org/10.1097/MCG.0b013e3180500348

42. Vassiliadis T, Anagnostis P, Patsiaoura K, Giouleme O, Katsinelos P, Mpoumponaris A, Eugenidis N. Valeriana hepatotoxicity. Sleep Med. 2009;10(8):935. https://doi.org/10.1016/j.sleep.2008.09.009

43. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, et al. Drug-induced liver injury: results from the hospital-based Berlin case-control surveillance study. Br J Clin Pharmacol. 2015;79(6):988–99. https://doi.org/10.1111/bcp.12565

44. Wu Y, Sun L, Zeng F, Wu S. A conjugated-polymer-based ratiometric nanoprobe for evaluating in vivo hepatotoxicity induced by herbal medicine via MSOT imaging. Photoacoustics. 2019;13:6–17. https://doi.org/10.1016/j.pacs.2018.11.002

45. Ma X, Peng JH, Hu YY. Chinese herbal medicin-induced liver injury. J Clin Transl Hepatol. 2014;2(3):170–5. https://doi.org/10.14218/JCTH.2014.00009

46. Chau TN, Cheuny WI, Ngan T, Lin J, Lee KWS, Poon WT, et al. Causality assessment of herb-ibduced liver injury using multidisciplinary approach and the Roussel Uclaf Causality assessment Method (RUCAM). Clin Toxicol. 2011;49(1):34–9. https://doi.org/10.3109/15563650.2010.537662

47. Teschke R, Schwarzenboeck A, Hennermann K. Kava hepatotoxicity: a clinical cases and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol. 2008;20(12):1182–93. https://doi.org/10.1097/MEG.0b013e3283036768

48. Bagins CI, Derag G, Baumelou A, Le Quintrec M, Vanherweg­hem JL. Herbs and the kidney. Am J Kidney Dis. 2004;44(1):1–11. http://dx.doi.org/10.1053/j.ajkd.2004.02.009

49. Jain A, Olivero JJ. Herbal nephropathy. Methodist Debakey Cardiovasc J. 2019;15(3):228–30.

50. Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acids as a probable human cancer in herbal remedies: a review. Mutagenesis. 2002;17(4):265–77. https://doi.org/10.1093/mutage/17.4.265

51. Jadot I, Declèves AE, Nortier J, Caron N. Decleves an integrated view of Aristolochic acid nephropathy: update of the literature. In J Mol Sci. 2017;18(2):297. https://doi.org/10.3390/ijms18020297

52. Stiborová M, Hudeček J, Frei E, Schmeiser HH. Contribution of biotransformation enzymes to the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions, difficult answers. Interdisc Toxicol. 2008;1(1):8–12. https://doi.org/10.2478/v10102-010-0023-1

53. Sun M, Zhang J, Zheng C, Liu Y, Lin F, Xu F, Chen C. Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China. Renal Failure. 2015;37(2):209–13. https://doi.org/10.3109/0886022X.2014.990347

54. Leung EMK, Chan W. Camparison of DNA and RNA adduct formation: significantly higher levels of RNA than DNA modificantions in the internal organs of aristolochic acid-dosed rats. Chem Res Toxicol. 2015;28(2):248–55. https://doi.org/10.1021/tx500423m

55. Li YY, Lu XY, Wang QQ, Zhang YD, Zhang JB, Fan XH. Potential hepatic and renal biflavonoids from Ginkgo biloba. Chin J Nat Med. 2019;17(9):672–81. https://doi.org/10.1016/S1875-5364(19)30081-0

56. Liew ZH, Lee KG. Liquorice-induced severe hypokalaemic rhabdomyolysis with acute kidney injury. Ann Acad Med Singapore. 2017;46(9):354–5.

57. Yase H, Foh T, Mizuno Y, Harada E. Severe hypokalemia, rhabdomyolysis, muscle paralysis and respiratory impairment in a hypertensive patient taking herbal medicines containing licorice. Intern Med. 2007;46(9):575–8. https://doi.org/10.2169/internalmedicine.46.6316

58. Батюшин ММ, Садовничая НА, Руденко ЛИ, Повилайтите ПЭ. Клинический случай нефропатии, обусловленной применением Репешка обыкновенного (Agrimonia eupatoria). Вестник Урологии. 2013;(3):30–8. https://doi.org/10.21886/2308-6424-2013-0-3-30-38

59. Nayeri A, Wu S, Adams E, Tanner C, Meshmans S, Saini I, Reid W. Acute calcincurin inhibitor nephrotoxicity secondary to turmeric intake: a case report. Transplant Proc. 2017;49(1):198–200. https://doi.org/10.1016/j.transproceed.2016.11.029

60. Carbajal R, Yisfalem A, Pradhan N, Baumstein D, Chaudhari A. Case report: boldo (Peumus boldus) and tacrolimus interaction in a renal transplant patient. Transplant Proc. 2014;46(7):2400–2. https://doi.org/10.1016/j.transproceed.2014.01.021

61. Nowack R, Nowak B. Herbal teas interfere with cyclosporin levels in renal transplant patients. Nephrol Dial Transplant. 2005;20(11):2554–6. https://doi.org/10.1093/ndt/gfi003

62. Burdman EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23(5):465–76. https://doi.org/10.1016/s0270-9295(03)00090-1

63. Egashira K, Sasaki H, Higuchi S, Ieiri I. Food-drug interaction of tacrolimus with pomelo, ginger and turmeric juice in rats. Drug Metab Pharmacokinet. 2012;27(2):242–7. https://doi.org/10.2133/dmpk.dmpk-11-rg-105

64. Zhang W, Lim LY. Effects of spice constituents on P-glycoprotein-mediated transplant and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos. 2008;36(7):1283–90. https://doi.org/10.1124/dmd.107.019737

65. Chen XW, Sneed KB, Pan SY, Cao C, Kanwar JR, Chew H, et al. Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metab. 2012;13(5):640–51. https://doi.org/10.2174/1389200211209050640

66. Cho HJ, Yoon IS. Pharmacokinetic interactions of herbs with cytochrome P450 and P-glycoprotein. Evid Based Complement Alternat Med. 2015;2015:736431. https://doi.org/10.1155/2015/736431

67. Ramos-Esquivel A, Viquez-Jaikel A, Fernandez K. Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract. 2017;13(17):e613–e622. https://doi.org/10.1200/JOP.2017.020859

68. Грибакина ОГ, Колыванов ГБ, Литвин АА, Виглинская АО, Жердев ВП Фармакокинетические взаимодействия лекарственных веществ, метаболизируемых изоферментом цитохрома Р450 CYP2С9. Фармакокинетика и фармакодинамика. 2016;(1):21–32.

69. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89–100. https://doi.org/10.1016/j.clpt.2003.09.013

70. Bossaer JB, Odle BL. Probable etoposide interaction with Echinacea. J Diet Suppl. 2012;9(2):90–5. https://doi.org/10.3109/19390211.2012.682643

71. Strippoli S, Lorusso V, Albano A, Guida M. Herbal-drug interaction induced rhabdomyolisis in a liposarcoma patient receving trabectedin. BMC Complement Altern Med.2013;13:199. https://doi.org/10.1186/1472-6882-13-199

72. Braunlich M, Christensen H, Johannesen S, Slimestad R, Wangensteen H, Malterud KE, Barsett H. In vitro inhibition of cytochrome P4503A4 by Aronia melanocarpa constituents. Planta Med. 2013;79(2):137–41. https://doi.org/10.1055/s-0032-1328055

73. Van Strater ACP, Bogers JPAM. Interaction of St. John’s wort (Hypericum perforatum) with clozapine. Int Clin Psychopharmacol. 2012;27(2):121–4. https://doi.org/10.1097/YIC.0b013e32834e8afd

74. Hussaarts KGAM, Hurkmans DP, Hoop EO, van Harten LJ, Berghuis S, van Alphen RJ. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019;11(3):403. https://doi.org/10.3390/cancers11030403

75. Muellers SC, Majcher-Peszynska J, Uehleke B, Klamnt S, Mundkowski RG, Miekisch W, et al. The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol. 2006;62(1):29–36. https://doi.org/10.1007/s00228-005-0061-3

76. Muellers SC, Majcher-Peszynska J, Mundkowsk RF, Uehleke B, Klamnt S, Sievers H, et al. No clinically relevant CYP3A4 induction after St. John’s wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol. 2009;65(1):81–7. https://doi.org/10.1007/s00228-008-0554-y

77. Arold G, Donath F, Maurer A, Diefenbach K, Dauer S, Henneicke-von Zepelin HH, et al. No revelant interaction with alprazolam, caffeine, tolbutamide and digoxin by treatment with a low-hyperforin St. John’s wort extract. Planta Med. 2005;71(4):331–7. https://doi.org/10.1055/s-2005-864099

78. Mai I, Bauer S, Perloff E, Johne A, Uehleke B, Frank B, et al. Hyperforin content determines the magnitude of the St. John’s wort-cyclosporine drug interaction. Clin Pharmacol Ther. 2004:76(4):330–40. https://doi.org/10.1016/j.clpt.2004.07.004

79. Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb-drug interactions: experiense with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841–50. https://doi.org/10.1097/00008571-200412000-00007

80. Moses GM, McGuire TM. Drug interactions with complementary medicines. Aust Prescr. 2010;33(6):177–80. https://doi.org/10.18773/austprescr.2010.084

81. Hodges PJ, Kam PCA. The peri-operative implications of herbal medicines. Anaesthesia. 2002;57(9):889–99. https://doi.org/10.1046/j.1365-2044.2002.02781.x

82. Diamond BJ, Baley MR. Ginkgo biloba: indications, mechanisms and safety. Psychiatr Clin North Am. 2013;36(1):73–83. https://doi.org/10.1016/j.psc.2012.12.006

83. Mai I, Störmer E, Bauer S, Krüger H, Budde K, Roots I. Impact of St Jobn`s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant. 2003;18(4):819–22. https://doi.org/10.1093/ndt/gfg002